Pharma Industry 2 min read Eli Lilly cuts Zepbound price to widen access for obesity drug Price for the 5 mg dose drops to $399 from $499, while higher doses will now be available at $449 per month under Lilly's Zepbound Self Pay Journey Program, down from $499 previously
By directly interacting with multiple hypothalamic circuits, GLP-1RAs also reduce appetite and food intake, leading to sustained weight loss in people with overweight and obesity [45]
Trabulo D, Marques S, Pedroso E
They use this approach selectively and safely, always backed by close monitoring and ongoing assessments
I may have even said on the episode, but I wasn't qualified enough to know for sure
Certain populations warrant extra caution: those with baseline GI dysmotility, diabetes-related neuropathy, or previous antibiotic resistance